Tabimorelin
Tabimorelin is an oral growth hormone secretagogue. Tabimorelin is a peptidomimetic agonist at the growth hormone secretagogue receptor with sufficient oral bioavailability for once-daily administration. It raises growth hormone and IGF-1, but development stopped after findings including hepatic enzyme elevation and inhibition of cytochrome P450 3A4, which raised interaction and safety concerns.
For research use only.
Key Facts
- CAS
- 193079-69-5
- Molecular Weight (MW)
- 528.7 g/mol
- Half-life
- —
- FDA status
- Withdrawn / Rejected
- Administration Route
- oral
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
Research summary
Orally active growth hormone secretagogue investigated for growth hormone deficiency. Development was discontinued. Not FDA-approved.
Peptide Library's Tabimorelin profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- —
- Frequency
- —
- Cycle
- —
- Administration Route
- oral
- Reconstitution Guide
- —
Sequence & molecular data
| Molecular formula | C32H40N4O3 |
|---|---|
| Molecular weight | 528.7 g/mol |
| CAS number | 193079-69-5 |
| PubChem CID | 9810101 |
| FDA UNII | L51CBE03KF |
| ChEMBL | CHEMBL281764 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Tabimorelin is a peptidomimetic agonist at the growth hormone secretagogue receptor with sufficient oral bioavailability for once-daily administration. It raises growth hormone and IGF-1, but development stopped after findings including hepatic enzyme elevation and inhibition of cytochrome P450 3A4, which raised interaction and safety concerns.
Studies
- Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency
- Pharmacokinetic and pharmacodynamic modeling of NN703, a growth hormone secretagogue, after a single po dose to human volunteers
- The pharmacokinetics, pharmacodynamics, safety and tolerability following 7 days daily oral treatment with NN703 in healthy male subjects
- The pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN703, a novel orally active growth hormone secretagogue in healthy male volunteers
- A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate
Regulatory & research status
Tabimorelin was withdrawn from the market or rejected for approval. It is not an approved product.
| FDA status | Withdrawn / Rejected |
|---|---|
| Research status | Development discontinued |
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Clinical Trial |
Benefits
—
Potential Side Effects
No side effects listed yet for this entry.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Tabimorelin: frequently asked questions
What is Tabimorelin?
Orally active growth hormone secretagogue investigated for growth hormone deficiency. Development was discontinued. Not FDA-approved.
How does Tabimorelin work?
Tabimorelin is a peptidomimetic agonist at the growth hormone secretagogue receptor with sufficient oral bioavailability for once-daily administration. It raises growth hormone and IGF-1, but development stopped after findings including hepatic enzyme elevation and inhibition of cytochrome P450 3A4, which raised interaction and safety concerns.
Is Tabimorelin FDA approved?
No. Tabimorelin is not currently FDA-approved. Its development or marketing was discontinued, which can happen for commercial reasons as well as safety or efficacy ones. Any material available today is not an approved product.
What peptides are similar to Tabimorelin?
Compounds most often compared with Tabimorelin include MK-677, Macimorelin, Anamorelin and Relamorelin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency — Clin Endocrinol (Oxf), 2003External reference
- Pharmacokinetic and pharmacodynamic modeling of NN703, a growth hormone secretagogue, after a single po dose to human volunteers — J Clin Pharmacol, 2001External reference
- The pharmacokinetics, pharmacodynamics, safety and tolerability following 7 days daily oral treatment with NN703 in healthy male subjects — Growth Horm IGF Res, 2001External reference
- The pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN703, a novel orally active growth hormone secretagogue in healthy male volunteers — Growth Horm IGF Res, 2000External reference
- A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate — Eur J Clin Pharmacol, 2003External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Tabimorelin profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Tabimorelin research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →